Cue Biopharma (CUE) Change in Receivables (2019 - 2025)

Cue Biopharma has disclosed Change in Receivables across 7 years of filings, most recently posting $5.2 million for Q4 2025.

• Change in Receivables for Q4 2025 came in at $5.2 million, up 333.76% year-over-year; the trailing twelve-month figure through Dec 2025 was $4.6 million (up 711.02% YoY), and the FY2025 annual result was $4.6 million, up 711.02% from the prior year.
• Change in Receivables came in at $5.2 million for Q4 2025 at Cue Biopharma, up from -$145000.0 in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $5.2 million in Q4 2025 to a low of -$2.2 million in Q1 2022.
• The 5-year median for Change in Receivables is $49000.0 (2022), against an average of $206452.2.
• Across the five-year window, Change in Receivables tumbled 55350.0% in 2022 and soared 776.67% in 2023, its largest moves.
• Cue Biopharma's Change in Receivables stood at $2.4 million in 2021, then tumbled by 131.13% to -$738000.0 in 2022, then surged by 105.15% to $38000.0 in 2023, then sank by 5907.89% to -$2.2 million in 2024, then jumped by 333.76% to $5.2 million in 2025.
• The last three Change in Receivables figures came in at $5.2 million (Q4 2025), -$145000.0 (Q3 2025), and $532000.0 (Q2 2025), per Business Quant data.